ProPhase Labs Inc  

(Public, NASDAQ:PRPH)   Watch this stock  
Find more results for PRPH
1.47
+0.07 (4.71%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.47 - 1.50
52 week 1.05 - 1.85
Open 1.50
Vol / Avg. 1,241.00/10,018.00
Mkt cap 25.32M
P/E     -
Div/yield     -
EPS -0.21
Shares 17.08M
Beta 0.13
Inst. own 20%
Aug 10, 2016
Q2 2016 ProPhase Labs Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 10, 2016
Q1 2016 ProPhase Labs Inc Earnings Release
Mar 29, 2016
Q4 2015 ProPhase Labs Inc Earnings Call - Webcast
Mar 29, 2016
Q4 2015 ProPhase Labs Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -24.88% -17.47%
Operating margin -23.91% -17.39%
EBITD margin - -15.61%
Return on average assets -38.07% -23.31%
Return on average equity -65.66% -36.84%
Employees 54 -
CDP Score - -

Address

621 N Shady Retreat Rd
DOYLESTOWN, PA 18901-2514
United States - Map
+1-215-3450919 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ProPhase Labs, Inc. is a manufacturer, marketer and distributor of a range of homeopathic and health products. The Company is also engaged in the research and development of potential over-the-counter (OTC) drugs, natural base health products along with supplements, personal care and cosmeceutical products. The Company's primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. The Company also manufactures, markets and distributes an organic cough drop and a Vitamin C supplement, Organix, and performs contract manufacturing services of cough drop, dietary supplements, and other OTC cold remedy products for third parties. The Company's flagship brand is Cold-EEZE Cold Remedy and its principal product is Cold-EEZE Cold Remedy zinc gluconate lozenges. Its product pipeline also includes Cold-EEZE Cold Remedy QuickMelts and Cold-EEZE Cold Remedy Oral Spray.

Officers and directors

Ted William Karkus Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Robert V. Cuddihy Jr. Chief Financial Officer, Chief Operating Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Mark A. Burnett Independent Director
Age: 55
Bio & Compensation  - Reuters
Louis Gleckel M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Mark Leventhal Independent Director
Age: 56
Bio & Compensation  - Reuters
James T. McCubbin Independent Director
Age: 51
Bio & Compensation  - Reuters